LAURA SCOTT: Open Payments
NPI 1679180244 · AMMON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$703 in 37 payments from 11 companies in 2025. Trend: 2023 $181 · 2024 $534 · 2025 $703
Food & beverage: $703
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $146 |
| Antares Pharma, Inc. | 8 | $131 |
| Aimmune Therapeutics, Inc. | 5 | $98 |
| Lilly USA, LLC | 4 | $81 |
| ABBVIE INC. | 4 | $74 |
| Novo Nordisk Inc | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
Products named: FANAPT, XYOSTED, MOUNJARO, ZENPEP, QULIPTA, Wegovy, GVOKE HYPOPEN, INJECTAFER.
Industry payments across ID — which companies pay providers there.
